

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

pAAV-RSV-SpCas9

RRID:Addgene_85450

Type: Plasmid

Proper Citation

RRID:Addgene_85450

Plasmid Information

URL: <http://www.addgene.org/85450>

Proper Citation: RRID:Addgene_85450

Insert Name: pRSV

Organism: Other

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:27246850](#)

Vector Backbone Description: Vector Backbone:pAAV; Vector Types:AAV; Bacterial Resistance:Ampicillin

Comments: We replaced the pMecp2 promoter of SpCas9 (Addgene: 60957) with a RSV (Rous Sarcoma Virus) promoter, which was amplified from a lentiviral vector for shRNA-MDM2

Plasmid Name: pAAV-RSV-SpCas9

Record Creation Time: 20220422T222550+0000

Record Last Update: 20260815T082124+0000

Ratings and Alerts

No rating or validation information has been found for pAAV-RSV-SpCas9.

No alerts have been found for pAAV-RSV-SpCas9.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Boender AJ, et al. (2023) An AAV-CRISPR/Cas9 strategy for gene editing across divergent rodent species: Targeting neural oxytocin receptors as a proof of concept. Science advances, 9(22), eadf4950.

Han H, et al. (2023) Leverage of nuclease-deficient CasX for preventing pathological angiogenesis. Molecular therapy. Nucleic acids, 33, 738.

Wu W, et al. (2021) AAV-mediated in vivo genome editing in vascular endothelial cells. Methods (San Diego, Calif.), 194, 12.

Moghadam F, et al. (2020) Synthetic immunomodulation with a CRISPR super-repressor in vivo. Nature cell biology, 22(9), 1143.